基于SEER数据库乳腺小管癌临床病理特征及预后因素分析
Analysis of Clinicopathological Features and Prognosis Factors of Tubular Carcinoma of the Breast Based on SEER Database
DOI: 10.12677/ACM.2022.12121625, PDF,   
作者: 韩若琳*, 徐 旸:西安医学院,陕西 西安;王虎霞:陕西省肿瘤医院,陕西 西安;宋张骏#:陕西省人民医院,陕西 西安
关键词: 乳腺癌小管癌生存分析预后SEER数据库Breast Cancer Tubular Carcinoma Survival Analysis Prognosis SEER Database
摘要: 目的:探讨乳腺小管癌的临床病理特征、预后及相关影响因素。方法:根据入组和排除标准从美国国立癌症研究监测、流行病学和最终结局(SEER)数据库中选择1973~2015年诊断为乳腺小管癌的1624例病例资料,回顾性分析其临床病理特征与生存情况,及其预后影响因素。结果:在1624例病人中,1557例(95.9%)为T1期,1554例(95.7%)为N0期,1599例(98.5%)接受手术治疗,915例(56.3%)接受放疗,90例(5.5%)接受化疗。病人3、5年总体生存率分别为97.4%、93.8%。单因素分析显示,年龄、婚姻状态、T分期、手术、放疗是影响乳腺小管癌病人生存预后的相关因素(P < 0.05)。多因素分析显示,年龄、婚姻状态、放疗是影响乳腺小管癌病人预后的独立危险因素(P < 0.05)。结论:影响乳腺小管癌患者预后的独立危险因素包括年龄、婚姻状态、放疗。放疗对乳腺小管癌患者的总生存率是否有益有待进一步研究探讨。
Abstract: Objective: To investigate the clinicopathological features, prognosis and related influencing factors of patients with tubular carcinoma of the breast. Methods: Data on 1624 cases diagnosed with tubular carcinoma of breast from 1973~2015 from Surveillance, Epidemiology, and End Results (SEER) database based on inclusion and exclusion criteria, the clinicopathological characteristics, survival and prognostic factors were retrospectively analyzed. Results: Among the selected 1624 patients with tubular carcinoma of breast, 1557 cases (95.9%) were T1 stage, 1554 cases (95.7%) were N0 stage, 1599 cases (98.5%) received surgery, 915 cases (56.3%) received radiotherapy, and 90 cases (5.5%) receive chemotherapy. The overall 3- and 5-year survival rates were 97.4% and 93.8%, respectively. Univariate analysis showed that age, marital status, T stage, surgery and radiotherapy were significantly associated with the prognosis of the patients with tubular carci-noma of breast (P < 0.05). Multivariate analysis revealed that age, marital status and radiotherapy were independent risk factors for prognosis of the patients with tubular carcinoma of breast (P < 0.05). Conclusion: The independent risk factors affecting the prognosis of patients with tubular car-cinoma of the breast are age, marital status and radiotherapy. Whether radiotherapy is beneficial to the survival of patients with tubular carcinoma of breast is still necessary to be further studied.
文章引用:韩若琳, 徐旸, 王虎霞, 宋张骏. 基于SEER数据库乳腺小管癌临床病理特征及预后因素分析[J]. 临床医学进展, 2022, 12(12): 11276-11284. https://doi.org/10.12677/ACM.2022.12121625

参考文献

[1] Chen, W., Zheng, R. and Baade, P.D. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[2] 李明, 王修珍. 乳腺小管癌6例及文献复习[J]. 中国实用医药, 2011, 6(9): 182-183.
[3] Rosen, P.P. (2001) Rosen’s Breast Pathology. 2nd Edition, Lippincott Williams & Wil-kins, Philadelphia.
[4] Lakhani, S., Ellis, I., Schnitt, S., et al. (2012) WHO Classification of Tumours of the Breast. 4th Edition, IARC Press, Lyon, 2-14.
[5] Wang, X.K., Hu, N., Herget, K., et al. (2019) The Effect of the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines in HER2 Positivity Rates among Women with Breast Cancer in SEER Registries. Cancer Research, 79, Abstract P4-02-15. [Google Scholar] [CrossRef
[6] Sharma, A., Jung, M.K., Polce, S.A., et al. (2019) Surveillance Epidemiology and End Results (SEER) Reported Survival Outcomes Have a High Accuracy and Positive Predictive Value When Tested Using Randomized Controlled Trials (RCTs) as Gold Standard. International Journal of Radiation Oncology, Biology, Physics, 105, E467-E468. [Google Scholar] [CrossRef
[7] Desantis, C., Ma, J., Bryan, L., et al. (2014) Breast Cancer Statistics, 2013. CA: A Cancer Journal for Clinicians, 1, 52-62. [Google Scholar] [CrossRef] [PubMed]
[8] Zandrino, F., Calabrese, M., Faedda, C., et al. (2006) Tubular Carcinoma of the Breast: Pathological Clinical and Ultrasonographic Findings. A Review of the Literature. La Radiologia Medica (Torino), 111, 773-782. [Google Scholar] [CrossRef] [PubMed]
[9] Rakha, E.A., Lee, A.H., Evans, A.J., et al. (2010) Tubular Car-cinoma of the Breast: Further Evidence to Support Its Excellent Prognosis. Journal of Clinical Oncology, 28, 99-104. [Google Scholar] [CrossRef
[10] Wu, Z.B. and Yang, G.H. (2002) Chinese Surgical Pathology. People’s Medical Publishing House, Beijing, 1658-1659.
[11] 郭冬梅, 杨爱国. 乳腺小管癌钼靶摄影和超声的特征表现[J]. 中国医学影像技术, 2009, 25(1): 94-95.
[12] Hamilton, L.J., Evans, A.J., Pinder, S.E., et al. (2004) Meta-static Carcinoma of the Breast with Tubular Features: Differences Compared with Metastatic Ductal Carcinoma of No Specific Type. Clinical Oncology, 16, 119-124. [Google Scholar] [CrossRef] [PubMed]
[13] Harris, M. and Ahmed, A. (1977) The Ultrastructure of Tubular Carcinoma of the Breast. The Journal of Pathology, 123, 79-83. [Google Scholar] [CrossRef] [PubMed]
[14] 金纯, 张筱骅. 乳腺小管癌11例临床分析[J]. 山东医药, 2006, 46(24): 51.
[15] Stolnicu, S., Moldovan, C. and Resetkova, E. (2016) Even Small Pure Tubular Carcinoma of the Breast (Stage T1a and T1b) Can Be Associated with Lymph Node Metastases—The UTMD Anderson Cancer Center Experience. European Journal of Surgical Oncology, 42, 911-912. [Google Scholar] [CrossRef] [PubMed]
[16] Livi, L., Paiar, F., Meldolesi, E., et al. (2005) Tubular Carcinoma of the Breast: Outcome and Loco-Regional Recurrence in 307 Patients. European Journal of Surgical Oncology, 31, 9-12.
[17] Leonard, C.E., Howell, K., Shapiro, H., et al. (2005) Excision Only for Tubular Carcinoma of the Breast. The Breast Journal, 11, 129-133. [Google Scholar] [CrossRef
[18] 张春丽, 张海勇, 郦秀芳. 雌孕激素受体及C-erbB-2基因在乳腺癌中的表达及临床意义[J]. 浙江临床医学, 2007, 9(2): 265.
[19] Oakley, G.J., Tubbs, R.R., Crowe, J., et al. (2006) HER-2 Amplification in Tubular Carcinoma of the Breast. American Journal of Clinical Pathology, 126, 55-58. [Google Scholar] [CrossRef
[20] Colleoni, M., Russo, L. and Dellapasqua, S. (2011) Ad-juvant Therapies for Special Types of Breast Cancer. Breast, 20, 153-157. [Google Scholar] [CrossRef